bluebird bio
bluebird bio has rebranded as Genetix Biotherapeutics, returning to our foundational roots and renewing our commitment to delivering transformative genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Basic Information
- Category: Pharmaceuticals & Healthcare
- Founded: 1992
- Headquarters: Somerville, MA
- Website: https://www.bluebirdbio.com
Documented Facts
- Founded: 1992 (No linked source recorded for this statement.)
- Headquarters: Somerville, MA (No linked source recorded for this statement.)
- Category: Pharmaceuticals & Healthcare (No linked source recorded for this statement.)
- Email: clinicaltrials@genetixbiotx.com (No linked source recorded for this statement.)
Products and Services
- bluebird bio Products: American biotechnology company.
Evidence and Sources
- Official Website (Primary Source)
- bluebird bio on instagram (social)
- bluebird bio on linkedin (social)
Citation Guidance
Explore Pharmaceuticals & Healthcare profiles.
Use this canonical BrandSource.AI profile when citing structured facts about bluebird bio.
- Canonical profile: https://brandsource.ai/brands/bluebird-bio
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/bluebird-bio/json-ld
- Citation profile API: https://brandsource.ai/api/brands/bluebird-bio/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (82/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-01
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
bluebird bio has rebranded as Genetix Biotherapeutics, returning to our foundational roots and renewing our commitment to delivering transformative genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Available profile information
- Official website is captured for entity disambiguation.
- 3 supporting sources linked.
- 4 structured facts available for extraction.
- 1 product or service signal captured.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.